GST-moms: Effects of Group-schematherapy on Mother-child Attachment Relations
Launched by MAASTRICHT UNIVERSITY · Oct 21, 2023
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called GST-moms, is studying how a special therapy called group-schematherapy can help mothers with young children improve their attachment and bond with their babies. When a new baby arrives, many mothers face stress that can make it hard for them to understand their baby’s needs. The goal of this study is to help mothers better manage their emotions and learn to respond to their babies in a way that fosters a strong emotional connection. By doing this, the researchers hope to improve the overall relationship between mothers and their children and prevent potential psychological issues for the child.
To participate in this study, mothers must be between the ages of 18 and 45 and have a child aged 0-5 years, while also having a specific type of personality disorder known as Cluster C. Unfortunately, mothers with certain other mental health conditions, such as severe depression or psychotic disorders, cannot participate. If eligible, participants can expect to join a supportive group where they’ll learn techniques to help them understand their feelings and their child’s needs better. This could be a valuable opportunity for mothers looking to strengthen their relationship with their children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible patients for the group schematherapy are mothers with young children (0-5 years), with a cluster C personality disorder.
- Exclusion Criteria:
- • Acute Suicidal or chronic suicidality
- • Psychotic disorder
- • Autistic spectrum disorder
- • Bipolar disorder
- • Developmental disorders
- • Any other AS-I disorder that requires treatment first (severe depression, alcohol and/or drugs abuse)
- • Cluster A or B personality disorders (traits of cluster B in combination with Cluster C personality disorder is included)
- • Neuropsychological damage
- • General problems for group therapy (auditory impairment, severe physical disability, insufficant Dutch comprehension, IQ \< 80)
- • Self-mutilation
About Maastricht University
Maastricht University is a leading academic institution in the Netherlands, renowned for its innovative approach to research and education in the health sciences. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials that aim to advance medical knowledge and improve patient outcomes. Maastricht University leverages its state-of-the-art facilities and expertise in various fields, including biomedical research, public health, and clinical practice, to conduct high-quality clinical studies that adhere to rigorous ethical standards. Committed to translating research findings into real-world applications, the university plays a pivotal role in addressing contemporary health challenges and enhancing healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jeffrey Roelofs, PhD
Principal Investigator
Maastricht University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported